BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jo IY, Son SH, Kim M, Sung SY, Won YK, Kang HJ, Lee SJ, Chung YA, Oh JK, Kay CS. Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33:179-187. [PMID: 26484301 DOI: 10.3857/roj.2015.33.3.179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hwang SH, Hong HS, Kim D, Kim GM, Lee HW, Lee M, Kim DY, Park MA, Yun M. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. Clin Nucl Med 2022. [PMID: 35384891 DOI: 10.1097/RLU.0000000000004128] [Reference Citation Analysis]
2 Kim DY, Park JW, Kim TH, Kim BH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim CM. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017;122:122-129. [PMID: 28034460 DOI: 10.1016/j.radonc.2016.12.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
3 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
4 Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. Liver Int. 2017;37:592-599. [PMID: 27804192 DOI: 10.1111/liv.13297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Review of Medical Devices 2019;16:341-50. [DOI: 10.1080/17434440.2019.1608817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
6 Sofia C, Cattafi A, Silipigni S, Pitrone P, Carerj ML, Marino MA, Pitrone A, Ascenti G. Portal vein thrombosis in patients with chronic liver diseases: From conventional to quantitative imaging. Eur J Radiol 2021;142:109859. [PMID: 34284232 DOI: 10.1016/j.ejrad.2021.109859] [Reference Citation Analysis]
7 Yu X, Zhu Y, Wang J, Song X, Zhu L, Men X, Li X, Dai D, Xu W. Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer. Nucl Med Commun 2017;38:193-200. [PMID: 27977537 DOI: 10.1097/MNM.0000000000000637] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Lim CH, Moon SH, Cho YS, Choi JY, Lee K, Hyun SH. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2019;46:1705-12. [DOI: 10.1007/s00259-019-04327-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ghosh S, Das T, Sarma HD, Banerjee S. Preparation and preliminary bioevaluation of 68Ga-oxine in lipiodol as a potential liver imaging agent. J Radioanal Nucl Chem 2017;311:263-8. [DOI: 10.1007/s10967-016-4985-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Yu JI, Park HC, Oh D, Noh JM, Jung SH, Kim HY, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial.Int J Hyperthermia. 2016;32:331-338. [PMID: 26915594 DOI: 10.3109/02656736.2016.1144895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]